作者
Xiaobin Shang,Yongjie Xie,Jinpu Yu,Chen Zhang,Gang Zhao,Fei Liang,Liang Liu,Wei Hong Zhang,Runmei Li,Wenwen Yu,Jie Yue,Chuangui Chen,Xiaofeng Duan,Zhao Ma,Zuoyu Chen,Yanjuan Xiong,Fan Yang,Jianyu Xiao,Rui Zhang,Pengpeng Liu,Yanan Cheng,Fuliang Cao,Feng Guo,Guoyan Liu,Bin Meng,Dejun Zhou,Yan Sun,Xiubao Ren,Jun Yu,Jihui Hao,Hongjing Jiang
摘要
In this phase II study, 47 patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) received three cycles of pembrolizumab plus chemotherapy, followed by Da Vinci robot-assisted surgery. The primary endpoints were safety and major pathological response (MPR). Key secondary endpoints included complete pathological response (pCR) and survival. No grade ≥3 adverse events or surgical delays occurred during neoadjuvant therapy. Among 46 patients studied for efficacy, the MPR and pCR rates were 72% and 41%, respectively. After a median follow-up of 27.2 months, the 2-year overall survival (OS) and disease-free survival (DFS) rates were 91% and 89%, respectively. Expansion of TRGC2